AR029466A1 - Nitrilos de dipeptidos, su proceso de sintesis y su uso para la preparacion de un medicamento en enfermedades en la cual la catepsina k este implicada - Google Patents
Nitrilos de dipeptidos, su proceso de sintesis y su uso para la preparacion de un medicamento en enfermedades en la cual la catepsina k este implicadaInfo
- Publication number
- AR029466A1 AR029466A1 ARP010100563A ARP010100563A AR029466A1 AR 029466 A1 AR029466 A1 AR 029466A1 AR P010100563 A ARP010100563 A AR P010100563A AR P010100563 A ARP010100563 A AR P010100563A AR 029466 A1 AR029466 A1 AR 029466A1
- Authority
- AR
- Argentina
- Prior art keywords
- het
- formula
- preparation
- katepsate
- nitrils
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Inhibidores del nitrilo de dipéptido catepsina K de la formula (1) y sales o ésteres farmacéuticamente aceptables de los mismos, en donde R1 y R2 son independientemente H o alquilo inferior de 1 a 7 átomos de carbono, o R1 y R2, junto con el átomo de carbono con el que están unidos forman un anillo cicloalquilo de 3 a 8 átomos de carbono, y Het es un sustituyente heterocíclico que contiene nitrogeno opcionalmente sustituido y Het no es 4-pirrol-1-ilo, utiles por ejemplo, para el tratamiento terapéutico o profiláctico de una enfermedad o condicion médica en donde esté implícita la catepsina K. Adicionalmente, un proceso para la preparacion de un compuesto de la formula (1), o una sal o éster del mismo, el cual comprende acoplar el derivado del ácido benzoico sustituido por Het correspondiente de la formula (3) en donde Het es como se define antes, con cianometilamida del ácido 1-amino-ciclohexan-carboxílico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0003111.2A GB0003111D0 (en) | 2000-02-10 | 2000-02-10 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR029466A1 true AR029466A1 (es) | 2003-07-02 |
Family
ID=9885359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP010100563A AR029466A1 (es) | 2000-02-10 | 2001-02-08 | Nitrilos de dipeptidos, su proceso de sintesis y su uso para la preparacion de un medicamento en enfermedades en la cual la catepsina k este implicada |
Country Status (31)
Country | Link |
---|---|
US (4) | US6642239B2 (es) |
EP (1) | EP1254124B1 (es) |
JP (1) | JP3942895B2 (es) |
KR (1) | KR100544553B1 (es) |
CN (2) | CN1183122C (es) |
AR (1) | AR029466A1 (es) |
AT (1) | ATE402930T1 (es) |
AU (1) | AU764334B2 (es) |
BR (1) | BR0108118A (es) |
CA (1) | CA2396158C (es) |
CO (1) | CO5261578A1 (es) |
CZ (1) | CZ20022721A3 (es) |
DE (1) | DE60135087D1 (es) |
ES (1) | ES2310177T3 (es) |
GB (1) | GB0003111D0 (es) |
HK (1) | HK1050197A1 (es) |
HU (1) | HUP0300148A3 (es) |
IL (1) | IL150406A0 (es) |
MX (1) | MXPA02007768A (es) |
MY (1) | MY122826A (es) |
NO (1) | NO20023780D0 (es) |
NZ (1) | NZ519940A (es) |
PE (1) | PE20020220A1 (es) |
PL (1) | PL200119B1 (es) |
PT (1) | PT1254124E (es) |
RU (2) | RU2265601C2 (es) |
SK (1) | SK11462002A3 (es) |
TR (1) | TR200201752T2 (es) |
TW (1) | TWI258473B (es) |
WO (1) | WO2001058886A1 (es) |
ZA (1) | ZA200206218B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9723407D0 (en) * | 1997-11-05 | 1998-01-07 | Ciba Geigy Ag | Organic compounds |
KR100688740B1 (ko) | 1999-03-15 | 2007-02-28 | 액시스 파마슈티컬스 인코포레이티드 | 프로테아제 억제제로서의 n-시아노메틸 아미드 |
GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US7723303B2 (en) * | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
US7199102B2 (en) * | 2000-08-24 | 2007-04-03 | The Regents Of The University Of California | Orally administered peptides synergize statin activity |
JP2004523506A (ja) | 2000-12-22 | 2004-08-05 | アクシス・ファーマシューティカルズ・インコーポレイテッド | カテプシン阻害剤としての新規な化合物と組成物 |
US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
EP1436255A1 (en) | 2001-09-14 | 2004-07-14 | Aventis Pharmaceuticals, Inc. | Novel compounds and compositions as cathepsin inhibitors |
KR20050044497A (ko) | 2001-11-14 | 2005-05-12 | 아벤티스 파마슈티칼스 인크. | 올리고펩티드 및 카텝신 s 억제제로서 이를 포함하는조성물 |
WO2003075836A2 (en) * | 2002-03-05 | 2003-09-18 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
CA2506114A1 (en) * | 2002-12-05 | 2004-06-24 | Axys Pharmaceuticals, Inc. | Cyanomethyl derivatives as cysteine protease inhibitors |
US7405229B2 (en) * | 2003-06-30 | 2008-07-29 | Merck Frosst Canada & Co. | Cathepsin cysteine protease inhibitors |
PE20050328A1 (es) * | 2003-07-21 | 2005-06-16 | Novartis Ag | Combinaciones de un bisfosfonato y un inhibidor de catepsina k |
JP2007511548A (ja) * | 2003-11-19 | 2007-05-10 | ノバルティス アクチエンゲゼルシャフト | 重篤な骨量減少疾患におけるカテプシンk阻害剤の使用 |
US7915300B2 (en) | 2004-01-08 | 2011-03-29 | Medivir Ab | Cysteine protease inhibitors |
CN101065137A (zh) * | 2004-09-16 | 2007-10-31 | 加利福尼亚大学董事会 | 用于改善动脉粥样硬化和其它病变的g型多肽和其它剂 |
US7579319B2 (en) * | 2004-12-06 | 2009-08-25 | The Regents Of The University Of California | Methods for improving the structure and function of arterioles |
GB0427380D0 (en) * | 2004-12-14 | 2005-01-19 | Novartis Ag | Organic compounds |
US20080125442A1 (en) * | 2005-01-19 | 2008-05-29 | Michael David Percival | Cathepsin K Inhibitors and Atherosclerosis |
US20090005323A1 (en) * | 2005-01-19 | 2009-01-01 | Michael David Percival | Cathepsin K Inhibitors and Obesity |
US20080293639A1 (en) * | 2005-04-29 | 2008-11-27 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
GB0517637D0 (en) * | 2005-08-30 | 2005-10-05 | Novartis Ag | Organic compounds |
JP3975226B2 (ja) * | 2006-01-11 | 2007-09-12 | 生化学工業株式会社 | シクロアルキルカルボニルアミノ酸誘導体及びその製造方法 |
WO2007080884A1 (ja) | 2006-01-11 | 2007-07-19 | Seikagaku Corporation | シクロアルキルカルボニルアミノ酸エステル誘導体及びその製造方法 |
JP4047365B2 (ja) | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | シクロアルカンカルボキサミド誘導体及びその製造方法 |
WO2007137149A2 (en) * | 2006-05-22 | 2007-11-29 | Velcura Therapeutics, Inc. | Use of cathepsin k antagonists in bone production |
GB0614044D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
GB0614053D0 (en) * | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
GB0614046D0 (en) | 2006-07-14 | 2006-08-23 | Amura Therapeutics Ltd | Compounds |
CN101970007A (zh) | 2007-06-08 | 2011-02-09 | 日本化学医药株式会社 | 脑动脉瘤的治疗或预防药 |
BRPI0702541A2 (pt) | 2007-06-21 | 2009-02-10 | Petroleo Brasileiro Sa | processo de craqueamento catalÍtico para produÇço de diesel a partir de sementes de oleaginosas |
US7893067B2 (en) | 2007-06-27 | 2011-02-22 | Medivir Ab | Cysteine protease inhibitors |
US20100331545A1 (en) | 2007-10-24 | 2010-12-30 | Nippon Chemiphar Co., Ltd. | Regulator for signaling toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
WO2009076490A1 (en) * | 2007-12-12 | 2009-06-18 | Velcura Therapeutics, Inc. | Use of cathepsin l antagonists in the treatment of bone disease |
JP5587790B2 (ja) | 2008-01-09 | 2014-09-10 | アミュラ セラピューティクス リミティド | 化合物 |
EP2262783A2 (en) * | 2008-02-21 | 2010-12-22 | Sanofi-Aventis | Covalently binding imaging probes |
GB0817425D0 (en) * | 2008-09-24 | 2008-10-29 | Medivir Ab | Protease inhibitors |
US20100298507A1 (en) * | 2009-05-19 | 2010-11-25 | Menschig Klaus R | Polyisobutylene Production Process With Improved Efficiencies And/Or For Forming Products Having Improved Characteristics And Polyisobutylene Products Produced Thereby |
US9943522B2 (en) | 2011-05-16 | 2018-04-17 | Bayer Intellectual Property Gmbh | Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure |
EP2537532A1 (en) | 2011-06-22 | 2012-12-26 | J. Stefan Institute | Cathepsin-binding compounds bound to a nanodevice and their diagnostic and therapeutic use |
US9593138B2 (en) | 2012-10-05 | 2017-03-14 | Wayne State University | Nitrile-containing enzyme inhibitors and ruthenium complexes thereof |
JP6226437B2 (ja) | 2013-06-14 | 2017-11-08 | 生化学工業株式会社 | α−オキソアシルアミノカプロラクタム体 |
US9481707B2 (en) | 2013-06-14 | 2016-11-01 | Seikagaku Corporation | α-oxoacyl amino-caprolactam derivative |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3467691A (en) | 1964-04-22 | 1969-09-16 | Tsutomu Irikura | N-(n-acylaminoacyl)-aminoacetonitriles |
US5206249A (en) | 1991-03-27 | 1993-04-27 | Du Pont Merck Pharmaceutical Company | Bis-naphthalimides containing amino-acid derived linkers as anticancer agents |
EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
JP3283114B2 (ja) | 1992-09-07 | 2002-05-20 | クミアイ化学工業株式会社 | 縮合ヘテロ環誘導体及び農園芸用殺菌剤 |
JP2848232B2 (ja) | 1993-02-19 | 1999-01-20 | 武田薬品工業株式会社 | アルデヒド誘導体 |
CN1078204C (zh) | 1993-04-28 | 2002-01-23 | 久美蓝化学工业株式会社 | 氨基酸酰胺衍生物及其杀真菌的用途和制备方法 |
JPH09501420A (ja) * | 1993-07-30 | 1997-02-10 | スミスクライン・ビーチャム・コーポレイション | 3−シアノ−3−(3,4−二置換)フェニルシクロヘキシル−1−カルボキシレート類 |
CA2173875A1 (en) | 1993-11-01 | 1995-05-11 | Hideyuki Saika | Endothelin receptor antagonists |
US5486623A (en) * | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
IL112759A0 (en) * | 1994-02-25 | 1995-05-26 | Khepri Pharmaceuticals Inc | Novel cysteine protease inhibitors |
PT749418E (pt) | 1994-03-10 | 2001-01-31 | Searle & Co | Derivados de l-n6-(1-iminoetil)lisina uteis como inibidores de oxido nitrico sintetase |
US5614649A (en) * | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5804560A (en) * | 1995-01-06 | 1998-09-08 | Sibia Neurosciences, Inc. | Peptide and peptide analog protease inhibitors |
CA2218716A1 (en) | 1995-04-21 | 1996-10-24 | Novartis Ag | N-aroylamino acid amides as endothelin inhibitors |
WO1997027200A1 (en) | 1996-01-26 | 1997-07-31 | Smithkline Beecham Plc | Thienoxazinone derivatives useful as antiviral agents |
WO1998001133A1 (fr) | 1996-07-08 | 1998-01-15 | Yamanouchi Pharmaceutical Co., Ltd. | Inhibiteurs de la resorption osseuse |
KR20000069075A (ko) | 1996-11-22 | 2000-11-25 | 진 엠. 듀발 | N-(아릴/헤테로아릴/알킬아세틸)아미노산 아미드, 이들을 함유하는 제약 조성물, 및 이들 화합물을 사용하여 베타-아밀로이드 펩티드의 방출 및(또는) 합성의 억제 방법 |
CN1273444C (zh) | 1997-11-05 | 2006-09-06 | 诺瓦提斯公司 | 二肽腈 |
GB9723407D0 (en) * | 1997-11-05 | 1998-01-07 | Ciba Geigy Ag | Organic compounds |
US6355678B1 (en) * | 1998-06-29 | 2002-03-12 | Parker Hughes Institute | Inhibitors of the EGF-receptor tyrosine kinase and methods for their use |
WO2000049008A1 (en) | 1999-02-20 | 2000-08-24 | Astrazeneca Ab | Di- and tripeptide nitrile derivatives as inhibitors of cathepsin l and cathepsin s |
EP1155010A1 (en) | 1999-02-20 | 2001-11-21 | AstraZeneca AB | Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsin s |
JP2002538151A (ja) | 1999-03-02 | 2002-11-12 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | カテプシンの可逆的インヒビターとして有用な化合物 |
KR100688740B1 (ko) | 1999-03-15 | 2007-02-28 | 액시스 파마슈티컬스 인코포레이티드 | 프로테아제 억제제로서의 n-시아노메틸 아미드 |
US6420364B1 (en) * | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
AU7490900A (en) * | 1999-09-16 | 2001-04-17 | Axys Pharmaceuticals, Inc. | Chemical compounds and compositions and their use as cathepsin s inhibitors |
JP2001139320A (ja) * | 1999-11-05 | 2001-05-22 | Asahi Glass Co Ltd | 球状シリカゲルの製造方法 |
BR0016699A (pt) * | 1999-12-24 | 2002-11-05 | Hoffmann La Roche | Compostos para o tratamento terapêutico e/ou profilático de distúrbios nos quais a catepsina "k" exerce uma função patológica significativa, processos para a manufatura dos mesmos e sua utilização |
ATE387199T1 (de) * | 2000-01-06 | 2008-03-15 | Merck Frosst Canada Ltd | Neue substanzen und verbindungen als protease- inhibitoren |
GB0003111D0 (en) * | 2000-02-10 | 2000-03-29 | Novartis Ag | Organic compounds |
-
2000
- 2000-02-10 GB GBGB0003111.2A patent/GB0003111D0/en not_active Ceased
-
2001
- 2001-02-02 TW TW090102220A patent/TWI258473B/zh not_active IP Right Cessation
- 2001-02-06 MY MYPI20010514A patent/MY122826A/en unknown
- 2001-02-07 US US09/778,302 patent/US6642239B2/en not_active Expired - Fee Related
- 2001-02-08 CN CNB018048099A patent/CN1183122C/zh not_active Expired - Fee Related
- 2001-02-08 JP JP2001558437A patent/JP3942895B2/ja not_active Expired - Fee Related
- 2001-02-08 WO PCT/EP2001/001359 patent/WO2001058886A1/en active IP Right Grant
- 2001-02-08 DE DE60135087T patent/DE60135087D1/de not_active Expired - Lifetime
- 2001-02-08 NZ NZ519940A patent/NZ519940A/en unknown
- 2001-02-08 HU HU0300148A patent/HUP0300148A3/hu unknown
- 2001-02-08 RU RU2002123350/04A patent/RU2265601C2/ru not_active IP Right Cessation
- 2001-02-08 TR TR2002/01752T patent/TR200201752T2/xx unknown
- 2001-02-08 EP EP01919270A patent/EP1254124B1/en not_active Expired - Lifetime
- 2001-02-08 AU AU46426/01A patent/AU764334B2/en not_active Ceased
- 2001-02-08 IL IL15040601A patent/IL150406A0/xx unknown
- 2001-02-08 RU RU2005108133/04A patent/RU2293732C2/ru active
- 2001-02-08 CZ CZ20022721A patent/CZ20022721A3/cs unknown
- 2001-02-08 AT AT01919270T patent/ATE402930T1/de active
- 2001-02-08 BR BR0108118-7A patent/BR0108118A/pt not_active Application Discontinuation
- 2001-02-08 CA CA002396158A patent/CA2396158C/en not_active Expired - Fee Related
- 2001-02-08 AR ARP010100563A patent/AR029466A1/es not_active Application Discontinuation
- 2001-02-08 SK SK1146-2002A patent/SK11462002A3/sk not_active Application Discontinuation
- 2001-02-08 PE PE2001000139A patent/PE20020220A1/es not_active Application Discontinuation
- 2001-02-08 ES ES01919270T patent/ES2310177T3/es not_active Expired - Lifetime
- 2001-02-08 MX MXPA02007768A patent/MXPA02007768A/es active IP Right Grant
- 2001-02-08 CN CNA2004100909449A patent/CN1636980A/zh active Pending
- 2001-02-08 PL PL357901A patent/PL200119B1/pl unknown
- 2001-02-08 KR KR1020027010280A patent/KR100544553B1/ko not_active IP Right Cessation
- 2001-02-08 PT PT01919270T patent/PT1254124E/pt unknown
- 2001-02-12 CO CO01010168A patent/CO5261578A1/es not_active Application Discontinuation
-
2002
- 2002-08-05 ZA ZA200206218A patent/ZA200206218B/en unknown
- 2002-08-09 NO NO20023780A patent/NO20023780D0/no unknown
-
2003
- 2003-04-03 HK HK03102397A patent/HK1050197A1/xx not_active IP Right Cessation
- 2003-04-09 US US10/410,377 patent/US20030203919A1/en not_active Abandoned
-
2005
- 2005-08-03 US US11/195,747 patent/US20050267129A1/en not_active Abandoned
-
2007
- 2007-04-23 US US11/738,878 patent/US20070191392A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR029466A1 (es) | Nitrilos de dipeptidos, su proceso de sintesis y su uso para la preparacion de un medicamento en enfermedades en la cual la catepsina k este implicada | |
ME01310B (me) | Derivati oksazola koji su supstituisani karboksilnom kiselinom za primenu kao ppar-alfa-1-gama aktivatori u lečenju dijabetesa | |
DK0638071T3 (da) | Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR) | |
AR100790A2 (es) | COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS | |
NZ592608A (en) | Benzoxazole kinase inhibitors and methods of use | |
WO2000021927A3 (en) | Pyrrole-2,5-diones as gsk-3 inhibitors | |
AR038762A1 (es) | Derivados de indolina, un proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion y el uso de dichos derivados para la fabricacion de un medicamento | |
RU2004109812A (ru) | Ингибиторы цистеинпротеазы 2-циано-4-аминопиримидинового строения с ингибирующим действием на катепсин к для лечения воспалительных и других заболеваний | |
NO20062905L (no) | Nye hydroksaminsyreestere og farmasoytisk anvendelse derav | |
AR076949A1 (es) | Derivados de 1h-imidazo-(4,5-c)-quinolinona | |
NO20051265L (no) | Anvendelse av og noen nye imidazopyridiner | |
SG151286A1 (en) | 5-substituted-2-phenylamino-benzamide as mek inhibitor | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
NO962811D0 (no) | Nye heterosykliske forbindelser | |
TW200745097A (en) | 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors | |
UA93393C2 (uk) | 1,3-діоксанкарбонові кислоти | |
HUP9800719A2 (hu) | N-helyettesített azaheterociklusos karboxilsavak és észtereik, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
TW200420545A (en) | 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives | |
AR038704A1 (es) | Derivados de tiazol como antagonistas del receptor nyp | |
AR050043A1 (es) | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares | |
CO5160245A1 (es) | Compuestos organicos inhibidores de las proteinasas de cisteina, en particular inhibidores de catepsina k de arilaminoalquilamida, y su uso farmaceutico para el tratamiento o la profilaxis de enfermedades o condiciones medicas en donde este implicada | |
HUP0203118A2 (hu) | Béta-diszubsztituált metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
TW200724138A (en) | Substituted carboxylic acid derivatives for the treatment of diabetes and lipid disorders, their preparation and use | |
KR20220115601A (ko) | 시스틴뇨증에 대한 시스틴 다이아미드 유사체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |